3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pancreatic Neoplasms
13
Prostatic Neoplasms
9
Carcinoma, Hepatocellular
8
Liver Neoplasms
6
Neoplasm Metastasis
3
Melanoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Unresectable Pancreatic Cancer
2
Stomach Neoplasms
2
Squamous Intraepithelial Lesions
2
Neoplasms
2
Lymphatic Metastasis
2
Locally Advanced Pancreatic Cancer
2
Kidney Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Adenocarcinoma Resectable
1
Pancreatic Adenocarcinoma Locally Advanced
1
Interventions
pembrolizumab
160
Carboplatin
143
Paclitaxel
125
Cyclophosphamide
93
130-nm albumin-bound paclitaxel
66
Capecitabine
63
Gemcitabine
54
Doxorubicin
49
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
40
Cisplatin
37
Nivolumab
34
sacituzumab govitecan
32
olaparib
32
Epirubicin
32
Docetaxel
28
eribulin
27
Specimen Handling
26
Bevacizumab
26
durvalumab
25
camrelizumab
23
Drug Therapy
22
Biopsy
22
Magnetic Resonance Spectroscopy
21
toripalimab
18
Radiotherapy
17
spartalizumab
16
Everolimus
15
fludarabine
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Triple Negative Breast Neoplasms
×
Electroporation
×
Clear all
NCT02531425
2023-05-15
TNBC
OncoSec Medical Incorporated
Phase 1
Completed
10 enrolled